• SenzaGen posted Q2 net sales of SEK 15.3 million, up 13% year on year.
• Operating loss narrowed to SEK 2.1 million from SEK 4.4 million; EPS improved to SEK -0.07 from SEK -0.13.
• H1 net sales rose 11% to SEK 30.2 million; operating loss narrowed to SEK 4.2 million.
• Cash and cash equivalents totaled SEK 35.5 million at June 30.
• CEO cited positive operating cash flow in Q2, stronger VitroScreen order intake, two major orders, and EU plans to phase out animal testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SenzaGen AB published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.